Ebbo, M., Grados, A., Daniel, L., Vely, F., Harle, J.R., Pavic, M. and Schleinitz, N. (2012) IgG4-Related Systemic Disease: Emergence of a New Systemic Disease? Literature Review. La Revue de Médecine Interne, 33, 23-34.
http://dx.doi.org/10.1016/j.revmed.2011.08.012

has been cited by the following article:

• TITLE: Anti-Thyroglobulin IgG in Therapeutic Immunoglobulins: A Reactivity Bias in IgG4 Subclass

  AUTHORS: Sonia Néron, Annie Roy, Nathalie Dussault, Caroline Philipeau

  KEYWORDS: IgG4, Anti-Thyroglobulin, Human Intravenous Immunoglobulin

  JOURNAL NAME: Open Journal of Immunology, Vol.4 No.3, September 1, 2014

  ABSTRACT: Therapeutic immunoglobulins are used in the treatment of immunodeficiencies as well as several autoimmune and inflammatory diseases. These intravenous immunoglobulins (IVIg) represent the healthy human IgG repertoire, which can be reactive for both self and non-self antigens. A better characterization of IVIg’s repertoire is an important aspect to enable its effective utilization as an immunomodulatory treatment. In this study we have investigated the reactivity of IgG1, IgG2, IgG3 and IgG4 present in IVIg for a small selection of antigens, including actin, DNA, ferritin and thyroglobulin. We observed that two commercial preparations of therapeutic immunoglobulins contain very high reactivity for thyroglobulin, which was predominantly detected by IgG4. Since IgG4 antibodies can have immunomodulatory properties, these result suggest that these anti-thyroglobulin may have a role in the IVIg treatment of autoimmune disease characterized by high avidity for anti-thyroglobulin antibodies such as Hashimoto’s disease.